Efficacy and Safety of Using Granules Dendrobii for the Treatment of Chronic Atrophic Gastritis
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Chronic atrophic gastritis (CAG) is a common and frequently-occurring disease, characterized
by atrophy of gastric mucosal epithelium and glands, thinning of the mucosa, thickening of
the submucosal muscle layer, intestinal metaplasia, and atypical hyperplasia. The course of
the disease is protracted and often recurrent, which seriously affects the work and physical
and mental health of the patient. Moreover, epidemiological studies have shown that the risk
of gastric cancer in patients with chronic multifocal atrophic gastritis is significantly
higher than that of the general population. Because CAG intestinal metaplasia and dysplasia
can easily develop into gastric cancer, the World Health Organization (WHO) listed CAG's
gastric mucosal atrophy, intestinal metaplasia and dysplasia as precancerous lesions of
gastric cancer in 1978. Therefore, reversing and disappearing the precancerous state of
gastric cancer is an effective measure to prevent the occurrence of gastric cancer.
The cause of CAG is complicated. Modern medicine believes that CAG is closely related to
biological factors, physical and chemical factors, immune factors, and genetic factors. At
present, there is no specific treatment, but symptomatic treatment is the main treatment. The
disease belongs to the categories of "stomach pain" and "suffocation" in traditional Chinese
medicine.
In many years of surveys and studies in Mainland China, it is found that Dendrobii granules
have a good effect on chronic atrophic gastritis. It is planned to explore the possibility,
effectiveness and safety of Dendrobii granules in the treatment of chronic atrophic gastritis
through clinical trials.
20 subjects will be randomized into the treatment group and placebo group with 18 weeks of
treatment.